Brinckerhoff Comments on Proposed Legislation Aimed at Curbing Drug Prices
01 January 2020
Partner Courtenay Brinckerhoff was quoted in a Law360 article, “Patent Legislation To Watch In 2020,” about a slew of pending bills aimed at curbing drug prices.
Brinckerhoff said the bills that have been proposed to date appear to need work and may not have their intended effect. “I don’t necessarily think they would achieve the intended purpose and would have a lot of unintended consequences,” she said. “Once people who understand the nitty gritty details of the patent system look at them, some of those will fall apart.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”